| 2009-11-16: |
Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre - Menopausal Women With Hypoactive Sexual Desire Disorder ( HSDD )
Ingelheim, Germany, November 16 ( PRN/ots ) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under - Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg (...) |
| 2009-11-12: |
Women with HIV: A Growing Challenge
Cologne, Germany, November 12 ( PRN/ots ) - - With Women Comprising Over Half of the Global HIV/AIDS Population,( 1 ) Leading Experts to Convene to Explore the Impact of Gender on Treatment and Care With 33 million individuals infected, HIV/AIDS has long been classified (...) |
| 2009-11-06: |
Ortho Clinical Diagnostics Launches First - of - its - kind Remote Monitoring Center in Europe
Paris, November 6 ( PRN/ots ) - - 24 Hour Central Command Center now Offers Predictive and Proactive Diagnostic Monitoring Service in Eight Languages to Clinical Laboratories in 18 Countries Using VITROS( R ) Systems PARIS, November 6 /PRNewswire/ - - Ortho Clinical Diagnostics ( OCD ) today announced the (...) |
| 2009-11-04: |
Ortho Clinical Diagnostics Launches First - of - its - kind Remote Monitoring Center in Europe
Paris, November 4 ( PRN/ots ) - - 24 Hour Central Command Center now Offers Predictive and Proactive Diagnostic Monitoring Service in Eight Languages to Clinical Laboratories in 18 Countries Using VITROS( R ) Systems Ortho Clinical Diagnostics ( OCD ) today announced the launch of a first - of - (...) |
| 2009-10-30: |
Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Survival
London ( PRN/ots ) - - Eisai Plans to Submit Marketing Authorization Applications for. Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer Eisai Co., Ltd. ( Headquarters: Tokyo, President and CEO: Haruo Naito ) today announced preliminary results from a recently completed Phase III study with (...) |
| 2009-10-26: |
Three European Analyses Showed Efient is Cost - Effective Compared with Clopidogrel in Patients with Acute Coronary Syndrome Undergoing PCI
Paris ( PRN/ots ) - Results from three separate European health economic analyses of the TRITON - TIMI 38 study showed that treatment with Efient( R ) ( prasugrel ) compared with clopidogrel ( Plavix( R ) ) reduced medical costs by lowering rehospitalisation rates and the need for repeat percutaneous coronary interventions ( PCI ), (...) |
| 2009-10-20: |
Excellence in Epilepsy Journalism Award
Brussels ( PRN/ots ) - - IBE and UCB Announce Winners of Award to Improve Understanding of Epilepsy Around the World The International Bureau of Epilepsy and UCB are pleased to announce the winners of the Excellence in Epilepsy Journalism Award 2009. To view the (...) |
| 2009-10-20: |
'Improvement through Movement' educational programme launched for people with osteoporosis / Pan - European osteoporosis patients encouraged to dance their way to stronger bones
Munich, Germany ( na Originaltextservice ) - An educational programme available on DVD is launched today, on World Osteoporosis Day, bringing together the glamorous world of ballroom dance with the serious nature of disease management. Sponsored by DAIICHI SANKYO EUROPE and endorsed by the (...) |
| 2009-10-09: |
Pieris reports preclinical development progress of its next generation VEGF antagonist / PRS - 050 program on track to commence clinical trials as planned
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic. Under its manufacturing agreement with Wacker (...) |
| 2009-10-09: |
New Data From the PRESTA Trial Demonstrate the Benefit of Enbrel( R ) in Patients With Psoriasis and Psoriatic Arthritis
Maidenhead, England ( PRN/ots ) - - Data Presented at the 18th EADV Congress add to the Comprehensive Long - Term Data set as Enbrel Reaches Five - Year Anniversary in Treating Patients With Plaque Psoriasis in Europe Data signalling that Enbrel( R ) ( etanercept ) can improve the quality (...) |
| 2009-10-05: |
Onglyza( R ) ( saxagliptin ) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabetes
Paris and London ( PRN/ots ) - Bristol - Myers Squibb Company ( NYSE: BMY ) and AstraZeneca ( NYSE: AZN ) ( LSE: AZN ) announced today that the European Commission has granted marketing authorisation for Onglyza in the 27 countries of the European Union. Onglyza is indicated as a once - (...) |
| 2009-10-05: |
Study Finds That ONGLYZA( TM ) ( saxagliptin ) When Added to Metformin was Non - Inferior to JANUVIA ( sitagliptin ) When Added to Metformin in Reducing Hemoglobin ( HbA1c ) in Adults With Type 2 Diabetes Mellitus
Princeton, New Jersey and London ( PRN/ots ) - Results from an 18 - week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA( TM ) ( saxagliptin ) 5 mg per day achieved (...) |
| 2009-10-01: |
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe
Osaka, Japan ( PRN/ots ) - Takeda Pharmaceutical Company Limited ( Osaka, Japan, "Takeda" ) announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP ( Turkey ), Takeda (...) |
| 2009-09-30: |
Superior Efficacy - dose Ratio for Lantus( R ) Over detemir
Paris ( PRN/ots ) - - 76 Prozent Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus( R ) Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today results of a head - to - head study providing further evidence on the efficacy of (...) |
| 2009-09-30: |
Muscle and Joint Pain Costs European Economies up to EUR240 Billion a Year
Brussels ( PRN/ots ) - - New Study Reveals Musculoskeletal Disorders ( MSDS ) Responsible for More Sick Days Than any Other Health Condition A new study today finds that musculoskeletal disorders ( MSDs ) account for nearly half ( 49 Prozent ) of all absences from work and 60 Prozent of permanent (...) |
| 2009-09-29: |
Resverlogix RVX - 208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Calgary, Canada ( PRN/ots ) - - Powerful Effects Seen in all Subjects Including Those With Low HDL - Representing a Majority of Myocardial Infarct Patients TSX Exchange Symbol: RVX Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX:RVX ) announced today that results from the Company's (...) |
| 2009-09-28: |
Boehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Pivotal Trials Programme for linagliptin
Ingelheim, Germany ( PRN/ots ) - - For Non - US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from (...) |
| 2009-09-28: |
Abbott to Acquire Solvay Pharmaceuticals Business
Abbott Park, Illinois ( PRN/ots ) - - Diversifies Abbott's pharmaceutical products, expanding international growth platform - Supports long - term strategy to bolster presence in key global emerging markets - Adds substantial R&D spending capacity to accelerate promising pipeline programs - Establishes Abbott's presence in the growing global (...) |
| 2009-09-25: |
Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data
Calgary, Canada ( PRN/ots ) - Resverlogix Corp. ( TSX:RVX ) announced today that it will host a live teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top (...) |
| 2009-09-25: |
Sanofi Aventis : Multaq( R ) ( dronedarone ) Recommended for Approval in the European Union
Paris ( PRN/ots ) - Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for (...) |
| 2009-09-25: |
Wyeth Receives Positive Opinion from European Regulators for its 13 - valent Pneumococcal Candidate Vaccine for Infants and Young Children
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that the European Medicines Agency's ( EMEA ) Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive opinion for the company's pneumococcal conjugate vaccine, Prevenar 13* ( Pneumococcal (...) |
| 2009-09-24: |
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
San Francisco ( PRN/ots ) - Abbott ( NYSE: ABT ) today announced primary results from its groundbreaking PROSPECT ( Providing Regional Observations to Study Predictors of Events in the Coronary Tree ) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable (...) |
| 2009-09-24: |
Vectibix( R ) in Combination With Chemotherapy Significantly Improves Progression - Free Survival in First - Line Metastatic Colorectal Cancer
Thousand Oaks, California ( PRN/ots ) - Amgen ( Nasdaq: AMGN ) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix( R ) ( panitumumab ) administered in combination with FOLFOX ( an oxaliplatin - based chemotherapy ) as the first - line treatment of metastatic colorectal cancer ( mCRC ). In this trial, (...) |
| 2009-09-23: |
Abbott's XIENCE V( R ) Superior to TAXUS( R ) in Key Safety and Efficacy Measures in SPIRIT IV Trial
San Francisco ( PRN/ots ) - At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS - 74 Percent Reduction in Stent Thrombosis ( Blood Clots ) Compared to TAXUS - Low Event (...) |
| 2009-09-23: |
Occlutech Receives Positive Ruling in German Proceeding Initiated by AGA Medical
Jena, Germany ( PRN/ots ) - Occlutech GmbH, the leading European developer of products for septal closure, today announced that the district court of Frankfurt, Germany reversed an earlier court injunction obtained by AGA Medical against Occlutech's sales and marketing activities relating to the newly launched (...) |
| 2009-09-22: |
Denosumab Demonstrates Superiority Over Zometa( R ) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Thousand Oaks, California ( PRN/ots ) - Amgen ( Nasdaq: AMGN ) today announced detailed results from a Phase 3, head - to - head trial evaluating denosumab versus Zometa( R ) ( zoledronic acid ) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its (...) |
| 2009-09-22: |
Vectibix( R ) in Combination With Chemotherapy Significantly Improves Progression - Free Survival in Second - Line Metastatic Colorectal Cancer
Thousand Oaks, California ( PRN/ots ) - Amgen ( Nasdaq: AMGN ) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix( R ) ( panitumumab ) in combination with FOLFIRI ( an irinotecan based chemotherapy ), as a second - line treatment for metastatic colorectal cancer ( mCRC ). In this trial, Vectibix (...) |
| 2009-09-22: |
Jane Seymour Lends Support to Recognise the Hopes and Achievements of People Living With Rheumatoid Arthritis ( RA )
Maidenhead, England ( PRN/ots ) - - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening (...) |
| 2009-09-21: |
Value of Text Verification Tool ( TVT ) Strongly Confirmed at RAPS in Philadelphia
Frankfurt ( na Originaltextservice ) - Trying economic times mean tight budgets. More projects, fewer people, rigid quality standards and competitve pressures are making the computer - driven proofreading tool made by Schlafender Hase more valuable than ever. Schlafender Hase GmbH of Frankfurt reported that (...) |
| 2009-09-21: |
Abbott's XIENCE V( R ) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long - Term Safety Results in SPIRIT III Trial
San Francisco ( PRN/ots ) - - Market - Leading XIENCE V Demonstrates Single - Digit Rate of Major Adverse Cardiac Events ( MACE ) at Three Years and a 43 Percent Reduction vs. TAXUS - No Additional Stent Thrombosis between Two and Three Years, and Impressive Low Rate of (...) |
| 2009-09-21: |
Roche to Present New Survival Data From Phase II, III and IV Studies for Avastin, Herceptin and Xeloda
Basel, Switzerland ( PRN/ots ) - - Nearly 150 Abstracts Covering New Tumour Types, New Patient Groups and Existing Indications to Feature in ECCO - ESMO Program Roche will present encouraging results from nearly 150 scientific studies investigating use of its major cancer medicines at (...) |
| 2009-09-16: |
Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation
Santa Clara, California ( PRN/ots ) - Guided Delivery Systems, Inc. ( "GDS" ) announced the first successful percutaneous implantation of the GDS Accucinch( R ) System for mitral valve repair. The procedure was performed by Prof. Dr. med. Joachim Schofer of Medizinisches Versorgungszentrum, Hamburg University Cardiovascular Center in (...) |
| 2009-09-15: |
New Analysis Supports Tiotropium as Initial Maintenance Therapy for COPD
Vienna ( PRN/ots ) - - Treatment With Tiotropium Reduced Lung Function Decline in Younger Patients NOT FOR US MEDIA A new post - hoc analysis of data from the Understanding Potential Long - term Impacts on Function with Tiotropium ( UPLIFT( R ) ) trial presented today at the European (...) |
| 2009-09-15: |
Wyeth Presents Data from Five - Year Vertebral Fracture Prevention Study with Bazedoxifene
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announces findings from a placebo - controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal (...) |
| 2009-09-15: |
Pieris AG enters into Anticalin Collaboration with Allergan, Inc.
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. ( NYSE: AGN ) that combines Pieris' proprietary Anticalin technology with Allergan's expertise in drug delivery and ophthalmic drug development with a goal (...) |
| 2009-09-07: |
Rheumatoid Arthritis ( RA ) Patients Taking Enbrel Keep Working for Longer
Maidenhead, England ( PRN/ots ) - - Study Published in Rheumatology Underscores the Need for Early and Aggressive Treatment to Maintain Work Productivity Patients receiving Enbrel( R ) ( etanercept ) in combination with methotrexate for early RA are more likely to continue working, according to the COMET study (...) |
| 2009-09-04: |
Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Stockholm ( PRN/ots ) - Karolinska Development ( publ ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the (...) |
| 2009-09-02: |
Pitavastatin Demonstrates no Significant Drug - to - Drug Interaction When Administered With CYP3A4 Inhibitors
Barcelona, Spain ( PRN/ots ) - - Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins New data presented at the European Society of Cardiology congress ( ESC ) demonstrated that the co - administration of the cytochrome inhibitor itraconazole has no clinically relevant effect on (...) |
| 2009-09-01: |
Edoxaban - next generation oral anticoagulant under investigation to help prevent stroke in patients with atrial fibrillation
Barcelona ( na Originaltextservice ) - New treatment could offer further option in addition to current standard of care in thromboembolic disease Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF - TIMI 48 ( Effective aNticoaGulation (...) |
| 2009-09-01: |
Pitavastatin is Non - Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 Weeks
Barcelona, Spain ( PRN/ots ) - - Pitavastatin Represents Long - Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia New phase III data presented at the European Society of Cardiology congress ( ESC ) demonstrated that pitavastatin is non - inferior to atorvastatin and simvastatin at (...) |
| 2009-08-31: |
Eight out of 10 People Diagnosed With Heart Disease Consider Their Diagnosis a 'Wake - Up Call'
Barcelona, Spain ( PRN/ots ) - - Your Heart: New Start initiative launched to provide heart patients and their carers with information about nutrition, fitness and medication adherence Eight out of 10 heart patients in an international survey of more than 3,000 patients felt their (...) |
| 2009-08-31: |
CRESTOR( R ) Reduced the Risk of Cardiovascular Events in Elderly Patients in New Analysis of JUPITER
Barcelona ( PRN/ots ) - A new analysis from the JUPITER study showed that CRESTOR( R ) ( rosuvastatin ) 20mg reduced the composite primary end point of major cardiovascular ( CV ) events ( combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes ) by 39 Prozent (...) |
| 2009-08-31: |
Neuromuscular Disease Treatment Catena( R ) Available in Europe on a Named Patient Basis
Liestal, Switzerland and Weybridge, England ( PRN/ots ) - - - Santhera and Idis Partner to Facilitate Patient Access to Friedreich's Ataxia Drug Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases and Idis announced today that Catena( R ) will be made available on (...) |
| 2009-08-31: |
Abbott Launches Next - Generation XIENCE PRIME( TM ) Drug Eluting Stent in International Markets
Barcelona, Spain ( PRN/ots ) - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes - Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott's Market - Leading XIENCE V( R ) Drug Eluting Stent Abbott ( NYSE: ABT ) today announced (...) |
| 2009-08-30: |
New Large - Scale, Global Study Provides Additional Information About an Intensified Dose - Regimen of PLAVIX( R ) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Paris, and Princeton, New Jersey ( PRN/ots ) - - No added benefit on the composite primary end - point with the higher dose when entire ACS study population considered - - Important new findings with higher loading dose of PLAVIX( R ) for heart patients undergoing coronary (...) |
| 2009-08-28: |
Data From Largest GOLD Stage II Patient Population Treated With Tiotropium Highlight the Benefits of Earlier Treatment of COPD
Ingelheim, Germany ( PRN/ots ) - - New UPLIFT( R ) Analysis Shows Tiotropium Significantly Improves Lung Function and Quality of Life in COPD Patients With Early Stage Disease - Not for US Media A new analysis of the landmark UPLIFT( R ) trial, published today in the Lancet, shows (...) |
| 2009-08-27: |
Wyeth's Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma
Maidenhead, England ( PRN/ots ) - Wyeth Europa Ltd., a division of Wyeth ( NYSE: WYE ), announced today that the European Commission has approved the mTOR ( mammalian target of rapamycin ) inhibitor TORISEL( R ) ( temsirolimus ) for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (...) |
| 2009-08-12: |
Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
Hong Kong and Lake Zurich, Illinois ( PRN/ots ) - Fenwal, Inc. of Lake Zurich, Illinois, and Golden Meditech ( stock code: 801.HK ) of Hong Kong, announced today they have agreed to form a joint venture in China to focus on blood collection and (...) |
| 2009-08-04: |
Novel Chemotherapy Agent Bendamustine Significantly More Effective First - Line Therapy Than Chlorambucil in CLL
Cambridge, England ( PRN/ots ) - - Blood Marrow Normalised in 31 Prozent ( Versus 2 Prozent ) of Patients, With Manageable Side - Effects Nearly a third ( 31 Prozent ) of all bendamustine - treated patients saw all clinical evidence of their advanced chronic lymphocytic leukaemia ( CLL ) disappear when used as a (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
